Benefits and Risks of Oral Diabetes Agents Compared With Insulin in Women With Gestational Diabetes: A Systematic Review
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Little is known about the comparative risks and benefits of medical treatments for gestational diabetes mellitus (GDM). We conducted a systematic review of randomized controlled trials and observational studies of maternal and neonatal outcomes in women with GDM treated with oral diabetes agents compared with all types of insulin. DATA SOURCES: We searched four electronic databases from inception through January 2007. Terms for GDM, insulins, and oral hypoglycemic agents were used in the search. Two investigators independently reviewed titles and abstracts, performed data abstraction on full articles, and assessed study quality. METHOD OF STUDY SELECTION: Articles were excluded if they had no comparison group or did not use a standard diagnosis of GDM (3-hour, 100-g oral glucose tolerance test or 2-hour, 75-g oral glucose tolerance test). Nine studies met our inclusion criteria, four randomized controlled trials (n=1,229 participants) and five observational studies (n=831 participants). Data were abstracted on study characteristics, gestational age at treatment, medication dosage, and length of follow-up. Outcomes included glycemic control, infant birth weight, neonatal hypoglycemia, and congenital anomalies. TABULATION, INTEGRATION, AND RESULTS: Two trials compared insulin to glyburide; one trial compared insulin, glyburide, and acarbose; and one trial compared insulin to metformin. No significant differences were found in maternal glycemic control or cesarean delivery rates between the insulin and glyburide groups. A meta-analysis showed similar infant birth weights between women treated with glyburide and women treated with insulin (mean difference -93 g) (95% confidence interval -191 to 5 g). There was a higher proportion of infants with neonatal hypoglycemia in the insulin group (8.1%) compared with the metformin group (3.3%) (P=.008). The rate of congenital malformations did not differ between pregnancies treated with insulin and those treated with oral agents. Observational studies were limited by selection bias and confounding. CONCLUSION: No substantial maternal or neonatal outcome differences were found with the use of glyburide or metformin compared with use of insulin in women with GDM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
ACOG Practice Bulletin No. 30: Gestational Diabetes
(2001) · Obstetrics & Gynecology · doi:10.1097/00006250-200109000-00037 · Cited by 301
RetractedGrading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“15* PW more than 90: 26 (13) 2 (1) Congenital malformation: 4 (2); NICU admission: 14 (7) 3,194 598 g”
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924 · cited 1×
“9% nullip P: 83 (22) Ind: 55 (15) As: 37 (10) O: 27 (7) M: 373 75-g WHO 33.”
The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study
HAPO Study Cooperative Research Group (2002) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(02)00092-9 · Cited by 401
Jacobson, G. F., Ramos, G. A., Ching, J. Y., Kirby, R. S., Ferrara, A., & Field, D. R. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.03.018 · Cited by 177
Chmait, R., Dinise, T., & Moore, T. (2004) · Journal of Perinatology · doi:10.1038/sj.jp.7211147 · Cited by 118
Use of glyburide for the treatment of gestational diabetes: the San Antonio experience
Conway, D. L., Gonzales, O., & Skiver, D. (2004) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050310001650725 · Cited by 112
Rochon, M., Rand, L., Roth, L., & Gaddipati, S. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.07.029 · Cited by 82
Cited by
Clinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318
“Metformin is increasingly being used to treat gestational diabetes.([50-52]) Metformin is carried across the placenta by transporters([53]) and the concentrations in the fetus are only slightly lower than in the mother.”
BackgroundGestational diabetes: the need for a common ground
Reece, E. A., Leguizamón, G., & Wiznitzer, A. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60515-8 · Cited by 589
Thompson, D., Berger, H., Feig, D., Gagnon, R., Kader, T., Keely, E., Kozak, S., Ryan, E., Sermer, M., & Vinokuroff, C. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.044 · Cited by 377
Randomized trial of metformin vs insulin in the management of gestational diabetes
Spaulonci, C. P., Bernardes, L. S., Trindade, T. C., Zugaib, M., & Francisco, R. P. V. (2013) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2013.03.022 · Cited by 183
Dhulkotia, J. S., Ola, B., Fraser, R., & Farrell, T. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2010.06.044 · Cited by 145
Metadata
- Authors
- Nicholson, W., Bolen, S., Witkop, C. T., Neale, D., Wilson, L., & Bass, E.
- Venue
- Obstetrics & Gynecology
- Published
- 2009-01
- Volume
- 113
- Issue
- 1
- Pages
- 193-205
- ISSN
- 0029-7844 (ISSN-L)
- OpenAlex
- W2170491513
- Cited by
- 161
- References
- 9
- FWCI
- 19.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benefits and Risks of Oral Diabetes Agents Compared With Insulin in Women With Gestational Diabetes: A Systematic Review. https://app.cochat.ai/papers/10.1097/aog.0b013e318190a459
- The paper
- Nicholson, W., Bolen, S., Witkop, C. T., Neale, D., Wilson, L., & Bass, E. (2009). Benefits and Risks of Oral Diabetes Agents Compared With Insulin in Women With Gestational Diabetes: A Systematic Review. Obstetrics & Gynecology. https://doi.org/10.1097/aog.0b013e318190a459
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.